目的 基于網(wǎng)絡(luò)藥理學(xué)方法分析魚腥草Houttuynia cordata治療病毒性肺炎的分子生物學(xué)機(jī)制，并對(duì)其防治新型冠狀病毒肺炎（COVID-19）的可行性進(jìn)行評(píng)估。方法 采用在線數(shù)據(jù)庫(kù)TCMSP、PubChem Search、Swiss target prediction、Genecards、OMIM獲得魚腥草活性成分、成分靶點(diǎn)及疾病靶點(diǎn)信息。借助Cytoscape3.7.1軟件構(gòu)建魚腥草活性成分-病毒性肺炎作用靶標(biāo)網(wǎng)絡(luò)，將靶蛋白運(yùn)用String10.0數(shù)據(jù)庫(kù)進(jìn)行蛋白質(zhì)相互作用（PPI）網(wǎng)絡(luò)分析，通過(guò)DAVID 6.8數(shù)據(jù)庫(kù)進(jìn)行基因本體論（GO）功能富集分析和京都基因與基因組百科全書（KEGG）通路富集分析，預(yù)測(cè)其作用機(jī)制。結(jié)果 從魚腥草中共篩選出16個(gè)主要活性成分，共涉及到311個(gè)靶點(diǎn)，與病毒性肺炎相關(guān)的靶點(diǎn)64個(gè)。從PPI網(wǎng)絡(luò)分析中發(fā)現(xiàn)關(guān)鍵靶點(diǎn)為IL2、TNF、AKT1、JUN、VEGFA、MAPK8、CXCL8、PTGS2等。GO和KEGG通路富集分析發(fā)現(xiàn)，魚腥草治療病毒性肺炎可能與細(xì)胞因子受體結(jié)合、細(xì)胞因子活性、受體配體活性、磷酸酶結(jié)合、蛋白磷酸酶結(jié)合、內(nèi)肽酶活性、生長(zhǎng)因子受體結(jié)合、腫瘤壞死因子受體超家族結(jié)合、絲氨酸型內(nèi)肽酶活性等73個(gè)GO功能有關(guān)，涉及到TNF信號(hào)通路、IL-17信號(hào)通路、C型凝集素受體信號(hào)通路、卡波西氏肉瘤相關(guān)皰疹病毒感染、甲型流感、Toll樣受體信號(hào)通路、T細(xì)胞受體信號(hào)通路、人巨細(xì)胞病毒感染、NOD樣受體信號(hào)通路等130個(gè)信號(hào)通路。結(jié)論 魚腥草針對(duì)病毒性肺炎具有多成分、多靶點(diǎn)、多機(jī)制的顯著治療作用，并且推測(cè)能夠通過(guò)調(diào)節(jié)與抗炎、抗病毒、免疫調(diào)節(jié)有關(guān)的生物通路對(duì)COVID-19進(jìn)行防御和治療。

Objective To analyze the molecular biological mechanism of Houttuynia cordata in treatment of viral pneumonia based on network pharmacology, and to evaluate its feasibility in prevention and treatment of Corona Virus Disease 2019 (COVID-19). Methods Online databases TCMSP, PubChem Search, Swiss Target Prediction, Genecards and OMIM were used to obtain the information of active components, component targets and disease targets of H. cordata. Cytoscape 3.7.1 software was used to construct the H. cordata activity-viral pneumonia target network, and the target protein was used to carry out protein-protein interaction (PPI) network using String10.0 database. Gene ontology (GO) functional enrichment analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis were performed using DAVID 6.8 database to predict the mechanism of action. Results A total of 16 main active components were screened from H. cordata, involving 311 targets, 64 targets related to viral pneumonia. The key targets of PPI network analysis were IL2, TNF, AKT1, JUN, VEGFA, MAPK8, CXCL8, PTGS2, etc. GO and KEGG pathway enrichment analysis found that its treatment of viral pneumonia may combine with cytokines receptors, cytokine activity, receptor ligands activity, as well as the combination of phosphatase, inside the protein phosphatase, peptide enzyme activity, growth factor receptor, tumor necrosis factor receptor superfamily combination, serine peptidase activity within about 73 function, 130 signaling pathways including TNF signaling pathway, IL-17 signaling pathway, C-type lectin receptor signaling pathway, Kapoussi's sarcoma associated herpes virus infection, influenza A, Toll-like receptor signaling pathway, T cell receptor signaling pathway, human cytomegalovirus infection, nod-like receptor signaling pathway were involved. Conclusion H. cordata for viral pneumonia has multiple components, multiple targets, multiple mechanisms of significant therapeutic effect, and speculated that can adjust the related to anti-inflammation, antivirus, immunomodulatory biological pathways of COVID-19 prevention and treatment.

R285.5

國(guó)家科技重大專項(xiàng)重大新藥創(chuàng)制項(xiàng)目：中醫(yī)藥優(yōu)勢(shì)領(lǐng)域的創(chuàng)新中藥關(guān)鍵技術(shù)開(kāi)發(fā)研究（2017ZX09301005）